601 related articles for article (PubMed ID: 9776134)
41. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Kannari K; Tanaka H; Maeda T; Tomiyama M; Suda T; Matsunaga M
J Neurochem; 2000 Jan; 74(1):263-9. PubMed ID: 10617128
[TBL] [Abstract][Full Text] [Related]
42. [Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
Ugrumov MV
J Soc Biol; 2009; 203(1):75-85. PubMed ID: 19358813
[TBL] [Abstract][Full Text] [Related]
43. Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.
Sarre S; Herregodts P; Deleu D; Devrieze A; De Klippel N; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):277-85. PubMed ID: 1407014
[TBL] [Abstract][Full Text] [Related]
44. Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum.
Neff NH; Wemlinger TA; Duchemin AM; Hadjiconstantinou M
J Pharmacol Exp Ther; 2006 May; 317(2):480-7. PubMed ID: 16415089
[TBL] [Abstract][Full Text] [Related]
45. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
Jackson D; Abercrombie ED; Zigmond MJ
J Pharmacol Exp Ther; 1993 Nov; 267(2):912-8. PubMed ID: 8246167
[TBL] [Abstract][Full Text] [Related]
46. L-DOPA does not facilitate nitric oxide production in the rat striatum and substantia nigra: in vivo microdialysis study.
Kashihara K; Sakai K; Marui K; Shohmori T
Life Sci; 1998; 63(4):PL59-64. PubMed ID: 9698040
[TBL] [Abstract][Full Text] [Related]
47. Fibroblasts that express aromatic amino acid decarboxylase have increased sensitivity to the synergistic cytotoxicity of L-dopa and manganese.
Montine TJ; Underhill TM; Linney E; Graham DG
Toxicol Appl Pharmacol; 1994 Sep; 128(1):116-22. PubMed ID: 8079344
[TBL] [Abstract][Full Text] [Related]
48. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
Yang J; Hu LF; Liu X; Zhou F; Ding JH; Hu G
Life Sci; 2006 Mar; 78(17):1940-4. PubMed ID: 16216278
[TBL] [Abstract][Full Text] [Related]
49. L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone.
Carey RJ; Pinheiro-Carrera M; Dai H; Tomaz C; Huston JP
Biol Psychiatry; 1995 Nov; 38(10):669-76. PubMed ID: 8555378
[TBL] [Abstract][Full Text] [Related]
50. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
51. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Brannan T; Knott P; Kaufmann H; Yahr M
Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
[No Abstract] [Full Text] [Related]
52. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Glavan G; Zivin M
Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
[TBL] [Abstract][Full Text] [Related]
53. Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
Serra PA; Esposito G; Enrico P; Mura MA; Migheli R; Delogu MR; Miele M; Desole MS; Grella G; Miele E
Br J Pharmacol; 2000 Jun; 130(4):937-45. PubMed ID: 10864903
[TBL] [Abstract][Full Text] [Related]
54. Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
Buck K; Voehringer P; Ferger B
Neuroscience; 2010 Mar; 166(2):355-8. PubMed ID: 20026252
[TBL] [Abstract][Full Text] [Related]
55. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
56. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Segovia G; Mora F; Crossman AR; Brotchie JM
Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
[TBL] [Abstract][Full Text] [Related]
57. Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Sarre S; De Klippel N; Herregodts P; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):15-21. PubMed ID: 7935849
[TBL] [Abstract][Full Text] [Related]
58. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
59. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
[TBL] [Abstract][Full Text] [Related]
60. Different levodopa actions on the extracellular dopamine pools in the rat striatum.
Rodríguez M; Morales I; González-Mora JL; Gómez I; Sabaté M; Dopico JG; Rodríguez-Oroz MC; Obeso JA
Synapse; 2007 Feb; 61(2):61-71. PubMed ID: 17117421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
